Navigation Links
ASGCT: Gene Therapy Shows Promise for Patients with Pompe Disease
Date:1/30/2010

New research in gene therapy is bringing doctors and patients closer to a comprehensive treatment for a rare disease portrayed in a new Hollywood film, according to the American Society of Gene & Cell Therapy.

Milwaukee (Vocus) January 30, 2010 -- New research in gene therapy is bringing doctors and patients closer to a comprehensive treatment for a rare disease portrayed in a new Hollywood film, according to the American Society of Gene & Cell Therapy.

“Extraordinary Measures” is based on the true story of John Crowley, a father struggling to find treatment for his children with Pompe disease, a rare, and often fatal, inherited disease that severely weakens the heart and lungs. Currently, the only approved treatment for Pompe is the enzyme-replacement medication Myozyme, which was ultimately developed by Genzyme Corporation.

In a study released this week in Molecular Therapy, ASGCT’s official journal, researchers at the University of Florida reported that gene therapy targeted at the diaphragms of mice with Pompe disease improved the ability of the mice to breathe independently.

This summer, six infants with the disease will receive the treatment. Although the treatment is not a cure, when used in conjunction with other therapies, like the drugs portrayed in the film, it is another step toward improving the lives of patients with Pompe disease.

“While the availability of Myozyme has been a life-saving therapy and a breakthrough for those living with Pompe disease, it must serve as a catalyst for continued innovation,” said Robert Mattaliano, PhD, group vice president of protein research and development at Genzyme. “Gene and cell-based therapies are at the forefront of such endeavors and bring the potential go to beyond replacing a missing enzyme by further improving the muscle repair process in this disease and others.”

Barry Byrne, MD, PhD, director of the Powell Gene Therapy Center at the University of Florida, is one of multiple doctors on which Harrison Ford’s character, Robert Stonehill, is based. Byrne also served as a technical advisor on the film.

"The movie focuses on John (Crowley) and the scientists he worked with to develop a treatment," Byrne said. "The filmmakers strived to create a story the audience will understand. I think it will resonate with people to see how much a parent will go through for his kids."

“Extraordinary Measures” follows John Crowley through his battle to secure funding for research, which eventually leads him partner with William Canfield, PhD, and Canfield’s pharmaceutical company, Novazyme, to develop a treatment for Pompe disease. Harrison Ford’s character is also based on Canfield. Prior to Novazyme finding a treatment, Novazyme was purchased by Genzyme Corporation. Following the purchase, Genzyme remained committed to developing a treatment for Pompe disease; on April 28, 2006, Myozyme was approved by the U.S Food and Drug Administration.

The American Society of Gene & Cell Therapy (ASGCT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, www.asgct.org.

# # #

Read the full story at http://www.prweb.com/releases/gene_and_cell_therapy/Pompe_disease/prweb3539914.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. AAPM statement on quality radiation therapy
2. Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services
3. Intensive Insulin Therapy Wont Boost Septic Shock Survival
4. Patients with resectable esophageal adenocarcinoma benefit from neoadjuvant chemoradiotherapy
5. Therapy May Relieve Breast Cancer Surgery Complication
6. ALS Therapy Development Institute Receives $1.6 Million Grant From the Department of Defense for Lou Gehrigs Disease Research
7. MBM ScienceBridge GmbH Negotiates License Agreement Between the Georg-August-University Gottingen, Universitatsmedizin, the University of Regensburg, and the UKs Medical Research Council Technology for a New Therapy of Inflammatory and Immune Disea
8. New hope for therapy in heartburn-related cancer
9. Breast cancer multigene test helping patients avoid chemotherapy
10. Psychotherapy May Help Teen Girls Avoid Obesity
11. After Cochlear Implant, Music Therapy May Aid Speech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... for supply chain management (SCM) and spend management, today announced that Keppel Corporation ... time, and simplify expense tracking. , “We are excited to announce the ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has ... for every household and family to know all about it for optimal health. Wanting ... the release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... five new hospital-grade power extension cords that meet the most current standards. , ... 2012 edition of the National Fire Protection Association (NFPA) 101 – Life Safety ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017  Bioness, Inc., the leading provider of ... first series of successful StimRouter Neuromodulation System implantations in ... Center (Nijmegen, Netherlands ), ... ), and Kliniek Park Leopold Chirec ( ... Bioness plans to further support clinicians across the continent ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 According ... (Spectroscopy, Chromatography), Measurement (On-Line, In-Line, At-Line), Products and Services (Analyzers, Probes & ... to 2021", published by MarketsandMarkets, the global market is poised to reach ... a CAGR of 13.3% from 2016 to 2021. ... ...
(Date:2/22/2017)... SEATTLE , Feb. 22, 2017 ... translational development of novel immune modulating therapies, today ... the a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust ... preclinical pain models. The study also establishes the ... the treatment of chronic pain. The findings were ...
Breaking Medicine Technology: